Why did Bunge file this 8-K, and does it announce a new transaction?

No. The filing does not announce a new deal. The Viterra acquisition was agreed in June 2023 and approved by Bunge shareholders in October 2023. This 8-K supplies the financial statements and pro forma information that Form 8-K Item 9.01 requires for a significant acquisition that has not yet closed.

How financially healthy was Viterra going into the deal?

Viterra was profitable but with declining earnings. 2023 net income fell to $453 million from $1,042 million in 2022, reflecting a Russia-related remeasurement loss and higher interest costs. In H1 2024, revenue dropped about 22% and net income fell to $70 million. Viterra had about $7.8 billion of borrowings and only $567 million of cash at June 30, 2024.

What would the combined company look like on a pro forma basis?

For FY2023, the pro forma combined company would have about $110 billion of net sales and $2.4 billion of net income attributable to Bunge, with pro forma diluted EPS of $11.27 compared with Bunge's reported $14.87. Pro forma results assume the deal closed on January 1, 2023 and exclude synergies, integration costs, and divested assets.

What are the main risks for Bunge shareholders from this deal?

Key risks include higher leverage from roughly $8 billion of new acquisition financing, dilution from issuing about 65.6 million shares, possible further regulatory conditions or delays beyond the EU remedies, and the possibility that the preliminary purchase price allocation (including $3.2 billion of goodwill) changes materially. Viterra's declining 2024 earnings also raise the question of whether projected synergies will be achieved, though the pro forma data exclude them.

BG 8-K SEC Disclosure — Sep 9, 2024

01—Abstract

Summary

Summary of the 8-K filed September 9, 2024. Cited figures are marked; the original filing is the authoritative source.

Bunge Global SA's September 9, 2024 Form 8-K is a financial-disclosure filing rather than a new transaction announcement: it supplies the required financial statements and pro forma information for the pending acquisition of Viterra Limited, a privately held Jersey-domiciled agricultural originator and marketer.

The Acquisition was agreed in June 2023, approved by Bunge shareholders in October 2023, and remains subject to regulatory approvals and customary closing conditions. The exhibits include Viterra's audited 2023 and 2022 financials (Deloitte, unmodified opinion), unaudited interim financials for the six months ended June 30, 2024, and Bunge's unaudited pro forma combined statements. Viterra's standalone results show a weaker 2024 trend.

Revenue for 2023 was $54.7 billion^a, down slightly from $53.9 billion in 2022, but net income fell from $1,042 million to $453 million, partly due to a $162 million remeasurement loss on Russian assets and higher interest expense ($573 million vs. $374 million). For the first half of 2024, revenue fell to $22.6 billion from $28.8 billion and net income dropped to $70 million from $141 million. Viterra's balance sheet carried roughly $7.7 billion of borrowings at year-end 2023 and about $7.8 billion at June 30, 2024, with cash of only $567 million.

The pro forma figures show the scale of the combination. On a combined basis for 2023, Bunge plus Viterra would have reported about $110.3 billion^b of net sales and $2.4 billion of net income attributable to Bunge, with pro forma diluted EPS of $11.27 versus Bunge's historical $14.87, reflecting the roughly 65.6 million new shares issued. Consideration is about 65.6 million Bunge shares plus about $2.0 billion in cash, and Bunge will also assume or repay roughly $9.8 billion of Viterra debt.

The pro forma data are preliminary: they exclude synergies and integration costs, and the purchase price allocation (including $3.2 billion^c of goodwill) may change materially. Pro forma figures also exclude Viterra's Russian operations, AOM, and the EU oilseeds assets that the European Commission required Viterra to divest in Hungary and part of Poland.

02—Key points

Key Highlights

Filing purpose: Item 8.01/9.01 supplement providing Viterra's audited FY2023 and FY2022 financial statements (Exhibit 99.1), unaudited H1 2024 interim statements (Exhibit 99.2), and Bunge pro forma combined financials (Exhibit 99.3) in connection with the pending Viterra acquisition.
Deal terms: about 65.6 million Bunge shares (about $6.8 billion at August 1, 2024 pricing) plus about $2.0 billion in cash, with Bunge also repaying or assuming roughly $3.7–9.8 billion of Viterra debt depending on the measure.
Viterra weakened in 2024: H1 2024 revenue fell about 22% year over year to $22.6 billion, and net income fell to $70 million from $141 million; 2023 net income was $453 million versus $1,042 million in 2022.
Leverage increase: Bunge financed the deal with $7.7 billion of committed term loans from an SMBC-led lender group plus a $300 million DDTL, implying higher interest expense; pro forma 2023 interest expense rises to about $1.0 billion from Bunge's historical $516 million.
Pro forma dilution: pro forma 2023 diluted EPS is $11.27 versus Bunge's historical $14.87, driven by share issuance and purchase accounting; the pro forma figures exclude any synergies or integration costs.
Regulatory conditions: the European Commission approved the deal subject to divesting Viterra's Hungarian business and part of its Polish oilseeds business, and the acquisition remains subject to other regulatory approvals and closing conditions.
Preliminary purchase accounting: fair value of consideration of about $12.5 billion, with preliminary goodwill of $3.2 billion; the final allocation may differ materially within the one-year measurement period.
Auditor and governance: Viterra's FY2023 statements were audited by Deloitte LLP under IFRS with an unmodified opinion; Deloitte's consent is filed as Exhibit 23.1.

03—Questions

Frequently Asked Questions

Why did Bunge file this 8-K, and does it announce a new transaction?
No. The filing does not announce a new deal. The Viterra acquisition was agreed in June 2023 and approved by Bunge shareholders in October 2023. This 8-K supplies the financial statements and pro forma information that Form 8-K Item 9.01 requires for a significant acquisition that has not yet closed.
How financially healthy was Viterra going into the deal?
Viterra was profitable but with declining earnings. 2023 net income fell to $453 million from $1,042 million in 2022, reflecting a Russia-related remeasurement loss and higher interest costs. In H1 2024, revenue dropped about 22% and net income fell to $70 million. Viterra had about $7.8 billion of borrowings and only $567 million of cash at June 30, 2024.
What would the combined company look like on a pro forma basis?
For FY2023, the pro forma combined company would have about $110 billion of net sales and $2.4 billion of net income attributable to Bunge, with pro forma diluted EPS of $11.27 compared with Bunge's reported $14.87. Pro forma results assume the deal closed on January 1, 2023 and exclude synergies, integration costs, and divested assets.
What are the main risks for Bunge shareholders from this deal?
Key risks include higher leverage from roughly $8 billion of new acquisition financing, dilution from issuing about 65.6 million shares, possible further regulatory conditions or delays beyond the EU remedies, and the possibility that the preliminary purchase price allocation (including $3.2 billion of goodwill) changes materially. Viterra's declining 2024 earnings also raise the question of whether projected synergies will be achieved, though the pro forma data exclude them.

04—Continue

← View all 8-K filings